AES Clinical Corner

Clinical Corner

AES Clinical Corner: Paxlovid

 

On December 22, 2021, the FDA issued an Emergency Use Authorization for Paxlovid™, a new COVID-19 oral antiviral medication. In addition to a summary of the key information from the FDA and other sources about related drug interactions and important considerations for providers with patients on antiseizure medications, the AES Treatments Committee discussed the issues in this convenient fifteen-minute AES Clinical Corner video.

Panel members include Barry Gidal, PharmD, FAES; Jon Cokley, PharmD; and David Vossler, MD, FAES.

See the summary linked below for more information on Paxlovid™ and considerations for providers with patients on ASMs.

Paxlovid Information from FDA and Guidance for AES Members

Clinical Corner features short-format video updates from experts on timely and important news and alerts in epilepsy.